Sean Duffy, M.D.
NPI 1306157128 · Pulmonary Disease Physician · Philadelphia, PA
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1306157128
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- Yes
- License
- MD452870 (PA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
15 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
702 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 136 | $132 |
| Critical Care, First 30-74 Minutes99291 | 113 | $214 |
| Test to Measure Expiratory Airflow and Volume94010 | 88 | $8 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 74 | $9 |
| Test for Exercise-Induced Lung Stress94618 | 61 | $22 |
| Test to Measure Expiratory Airflow and Volume Changes Before and After Medication Administration94060 | 51 | $10 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 18 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 173 | 52 |
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 141 | 31 |
| Umeclidinium Bromidebrand: Incruse Ellipta | 61 | 15 |
| Prednisone | 53 | 33 |
| Montelukast Sodium | 45 | 14 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 41 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$57 across 3 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2010-06-25
- Last updated
- 2016-06-22
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.